Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acologix, Inc.
Acologix AC-200 Demonstrates Positive Effect on Bone in Preclinical Model of Chronic Kidney Disease
November 21st, 2008
Acologix, Inc., a privately held biopharmaceutical company, will present data indicating that its therapeutic product candidate AC-200 improved bone architecture in a rat model of chronic kidney disease. AC-200, an endogenous human protein produced by bone cells, was evaluated in a well accepted rodent model of chronic kidney disease (CKD) in which bone loss is rapid and substantial. The data will be presented by David Rosen, Ph.D on November 8, 2008 at the 41st ASN (American Society of Nephrology) Annual Meeting in Philadelphia, PA. The effects of AC-200 on bone and mineral metabolism were evaluated in partially nephrectomized rats (5/6 Nx). These rats have reduced...
Source: Health Business Week (2008-11-21)
|
